

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Examining new-generation transdermal alcohol biosensor performance across laboratory and
field contexts

Talia Ariss^{a,1}, Catharine E. Fairbairn^{a,1}, and Nigel Bosch^{a,1}

^a University of Illinois—Urbana-Champaign, United States of America

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

Author Note

¹Talia Ariss, M.A., Department of Psychology, University of Illinois—Urbana-Champaign; Catharine E. Fairbairn, Ph.D., Department of Psychology, University of Illinois—Urbana-Champaign; Nigel Bosch, Ph.D., School of Information Sciences and Department of Educational Psychology, University of Illinois—Urbana-Champaign.

This research was supported by National Institutes of Health Grants R01AA028488 and R01AA025969 to Catharine E. Fairbairn. Our thanks to Brynne Velia, Laura Gurrieri, Dahyeon Kang, and Zoe Lee for their support with data collection for this study. C.E.F. received transdermal devices at discounted rates from BACtrack for the purposes of performing validation research. BACtrack did not have a role in conducting, evaluating, or disseminating the research. We have no known conflicts of interest to disclose.

Correspondence concerning this article should be addressed either to Talia Ariss, M.A., Department of Psychology, University of Illinois—Urbana-Champaign, 603 East Daniel St., Champaign, Illinois, USA, 61820, electronic mail: tariss2@illinois.edu, or to Catharine Fairbairn, Ph.D., Department of Psychology, University of Illinois—Urbana-Champaign, 603 East Daniel St., Champaign, Illinois, USA, 61820, electronic mail: cfairbai@illinois.edu.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Abstract

Background: Wrist-worn transdermal alcohol sensors have the potential to change how alcohol consumption is measured. However, hardware and data analytic challenges associated with transdermal sensor data have kept these devices from widespread use. Given recent technological and analytic advances, this study provides an updated account of the performance of a new generation wrist-worn transdermal sensor in both laboratory and field settings.

Methods: This work leverages machine learning models to convert transdermal alcohol concentration (TAC) data into estimates of Breath Alcohol Concentration (BrAC) in a large-scale laboratory (N=256, study 1) and pilot field sample (N=27, study 2). Specifically, in both studies, the accuracy of this translation is evaluated by comparing BAC estimates yielded from BACtrack Skyn to real-time breathalyzer measurements collected in the lab and in the field.

Results: The newest version of the Skyn device demonstrates a substantially lower error rate compared to older hand-assembled prototypes (0%-7% vs 29%-53%). On average, real-time estimates of BrAC yielded from these transdermal sensors are within 0.007 of true BAC readings in the laboratory context and within 0.019 of true BrAC readings in the field. In both contexts, distance between true and estimated BrAC was larger when only alcohol episodes were examined (0.017 lab; 0.041 field). Lastly, results of power-law-curve projections indicate the accuracy of transdermal BrAC estimates in real-world contexts has the potential to improve markedly (>25%) given adequately sized datasets for model training.

Conclusion: Findings from this study indicate the latest version of transdermal wrist sensor holds promise for the assessment of alcohol consumption in field contexts. A great deal of additional work is left to be done before we have a full picture of the utility of these devices, including research with large participant samples in field contexts.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

55

56 **Keywords:** Alcohol, Biosensor, Transdermal, Blood Alcohol Concentration, Machine Learning.

57

58

59 **Examining new-generation transdermal alcohol biosensor performance across laboratory**
60 **and field contexts**

61 Transdermal alcohol biosensors have received increasing attention from researchers as a
62 promising method for continuous, objective assessment of alcohol consumption (Fairbairn &
63 Kang, 2020). Designed to detect traces of alcohol expelled through the skin in the form of water
64 vapor and sweat, these non-invasive sensors have the potential to overcome many of the
65 limitations associated with traditional measures of intoxication (Nyman & Palmlov, 1936; Swift,
66 2003; Swift & Swette, 1992). Specifically, self-reports of alcohol consumption can be impacted
67 by self-presentational concerns and alcohol-related cognitive disruptions (Cherpitel et al., 2018;
68 Ernhart et al., 1988; White, 2003), improperly used breathalyzers can produce readings biased by
69 mouth alcohol (Caddy et al., 1978; Gullberg, 1992), and blood draws are impractical for use in
70 the field. In light of their ability to objectively and unobtrusively assess consumption patterns in
71 naturalistic environments, transdermal sensors have the potential to help users gain insight into
72 their drinking patterns and by extension minimize alcohol-related morbidity and mortality
73 (Fairbairn & Kang, 2020; Fridberg et al., 2022; Luczak et al., 2018; Piasecki, 2019).

74 Despite the potential of these sensors, challenges have emerged surrounding the
75 transdermal measurement of alcohol consumption that have precluded more widespread
76 application (Luczak & Ramchandani, 2019; Wang et al., 2019). The first of these challenges
77 pertains to the devices themselves, particularly in their earlier iterations. The Secure Continuous
78 Remote Alcohol Monitor (SCRAMTM; AMS, Littleton) is an early-generation transdermal ankle
79 bracelet that currently represents the most widely researched, validated, and utilized device on
80 the market (Dougherty et al., 2012; Fairbairn et al., 2019). SCRAM devices have been used in
81 the justice system as abstinence monitors (Leffingwell et al., 2013), in treatment settings to help

82 improve care (Dougherty et al., 2014), and in research studies to approximate blood alcohol
83 concentration (BAC) in the field (Fairbairn et al., 2018; Russell et al., 2022) . However, several
84 design elements of these ankle monitors prevent more widespread application beyond these more
85 specialized settings including a relatively bulky design, which causes embarrassment and skin
86 irritation in some users, and an active, pump-based method for assessing TAC that constrains
87 sampling to a relatively sparse 30-minute interval (Alessi et al., 2017; Caluzzi et al., 2019). The
88 second of these challenges pertains to the interpretation of the data yielded from these devices.
89 Several decades of research exploring transdermal alcohol sensor output has revealed that the
90 translation of transdermal alcohol concentration (TAC) data into estimates of BAC is not a
91 straightforward task (Fairbairn & Kang, 2020). Studies reveal that the relationship between TAC
92 and BAC can vary across individuals and also settings (Luczak et al., 2018; Saldich et al., 2021;
93 Wang et al., 2019), and further that TAC can lag behind BAC by variable intervals (Fairbairn &
94 Kang, 2019; Luczak & Ramchandani, 2019; Luczak & Rosen, 2014; Marques & McKnight,
95 2009; Sakai et al., 2006).

96 In recent years, advances in wireless communication, miniaturization, and big data
97 analytics have emerged with the potential to help overcome some of the challenges associated
98 with transdermal alcohol measurement (Fairbairn & Bosch, 2021). Such advances have
99 facilitated the development of a significantly smaller and lighter generation of transdermal
100 alcohol sensor, comparable in size to widely-available fitness smartwatches (Fairbairn & Kang,
101 2019; Wang et al., 2019). These new-generation sensors offer enhanced data storage capacity
102 facilitated by smartphone integration, thus permitting substantially more rapid TAC sampling (20
103 seconds) and a shorter lag time for the transdermal detection of alcohol (Fairbairn et al., 2020;
104 Wang et al., 2019). These new devices allow for more unobtrusive and immediate examination

105 of drinking behaviors, thus introducing novel applications for transdermal technology including
106 for widespread health monitoring and prevention in everyday drinkers (Barnett, 2015; Dougherty
107 et al., 2014; Fairbairn & Bosch, 2021). Recent years have also yielded advances in analytic
108 approaches for processing transdermal sensor data (Fairbairn & Bosch, 2021). Specifically, the
109 past decade has given rise to major progress in a family of computational approaches known as
110 machine-learning. Machine-learning algorithms are unique in their ability to model complex
111 relationships between variables, learning the shape of these associations directly from the data
112 itself rather than confining these relationships to a pre-determined set of forms (e.g., linear,
113 quadratic, logarithmic; Mjolsness & DeCoste, 2001). Thus, under optimal training conditions,
114 machine learning algorithms can model relationships between variables that take on an infinite
115 number of shapes, making these models uniquely successful in solving specific complex
116 translation problems including those involved in speech recognition and climate forecasting.
117 Importantly, the accuracy of machine learning output hinges on the nature of the data available
118 for training, with the potential complexity and sophistication of the model that can be applied
119 increasing as the size of the dataset increases (Frey & Fisher, 1999). Thus, larger datasets are
120 often necessary for machine learning applications. Nonetheless, given adequate data for model
121 training, the flexible approach offered within a machine learning framework has the potential to
122 address some of the challenges of TAC-BAC translation.

123 Although these devices and analytic tools show promise, they are as yet quite new and
124 thus little is known of how they might impact the broader viability of transdermal alcohol
125 measurement. Specifically, regarding these novel tools, several major gaps remain in our
126 knowledge of their feasibility for implementation as well as the validity of the alcohol use
127 estimates they yield. First, although early hand-assembled prototypes of new-generation

128 transdermal sensors showed high failure rates (Ash et al., 2022; Fairbairn & Kang, 2019) —with
 129 sensor failure rate ranging from 18% to 38%—relatively little is known of the performance of
 130 these sensors beyond the prototype phase. Three studies to date have reported on error rates of
 131 (non-prototype) new-generation sensors, one of which featured expert users rather than
 132 community samples (Wang et al., 2021), and two others that recruited a relatively small number
 133 of community participants (Ash et al., 2022; Merrill et al., 2022). Additional information on
 134 error rates in more recent new-generation sensor device builds is critical in determining the
 135 feasibility of applications for these sensors. Second, studies to date have featured extremely
 136 small sample sizes (Fairbairn & Kang, 2019; Wang et al., 2019) and a select few have sought to
 137 validate new-generation sensors in field settings (Ash et al., 2022; Merrill et al., 2022; Wang et
 138 al., 2021). We thus have little sense for how the accuracy of transdermal BAC estimates might
 139 be impacted given larger datasets available for model training. Data from larger participant
 140 samples will be necessary to establish the reliability, feasibility, and validity of these new-
 141 generation devices, with special attention allotted to the recruitment of diverse community
 142 samples across both laboratory and real-world settings.

143 The present study examines transdermal alcohol sensor accuracy using a multimodal
 144 design and is among the first studies to examine TAC-BAC translation for new-generation
 145 sensors in a field setting. Specifically, we combine a large-scale laboratory investigation of
 146 community recruits (N=256) with a pilot field sample (N=27), applying machine learning models
 147 to explore the accuracy of transdermal BAC estimates in datasets that vary both in their size as
 148 well as the conditions of sampling. Of note, a subset of the laboratory sample was included in
 149 previous publications assessing hand-assembled prototypes of new-generation sensors (see
 150 Fairbairn & Kang, 2019; Fairbairn et al., 2020 N = 72); the current study more that triples the

151 sample size of this study while also now integrating the newest build of new-generation sensor.
152 With the view to identify research designs suitable to TAC-BAC translation and for a glimpse
153 into future potential for transdermal sensors upon accrual of additional data, the current study
154 also integrates power-law-curve based projections predicting increases in field sensor accuracy
155 given larger datasets available for training. The aims of the current study are as follows: 1) Offer
156 (updated) error rates of machine-made new-generation sensors in a large community sample; 2)
157 Provide preliminary accuracy levels for BAC estimates from new-generation transdermal alcohol
158 sensors in field settings; 3) Explore the relationship between sample size and both actual
159 (laboratory) and projected (field) increases in accuracy given larger datasets available for model
160 training,

161

162 **Study 1**

163 **Method**

164 *Participants*

165 Participants in the study were young healthy social drinkers (ages 21-30). Participants
166 were recruited via advertisements posted in the local community as well as through social media.
167 Exclusion criteria were in line with guidelines for the administration of alcohol in human
168 subjects (National Advisory Council on Alcohol Abuse and Alcoholism, 1989; see also Fairbairn
169 & Kang, 2019). A total of 256 individuals underwent experimental procedures. Due to
170 equipment issues with early Skyn prototype devices (see “Device Failure” section of the results),
171 the final sample consisted of the 195 individuals for whom we were able to obtain Skyn
172 readings. Of this final sample, 110 were randomly assigned to the alcohol condition and 85 to the
173 no-alcohol condition. Regarding biological sex, 55% of participants identified as female and

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

174 45% male. Fifty-six percent of participants identified as White, 21% Asian, 6%, African-
175 American, and 17% as multiracial or other racial category.

176 *Procedure*

177 A complete description of procedures can be found elsewhere (Fairbairn et al., 2020;
178 Fairbairn & Kang, 2019). Upon arriving at the laboratory, participants were breathalyzed
179 (Intoximeters Alco-Sensor IV) to verify a 0.00% breath alcohol concentration (BrAC). After a
180 baseline period (1-2 hours), beverages were administered in 3 equal parts over 36 minutes.
181 Participants assigned to the alcohol condition received a dose intended to achieve a peak BAC
182 approximately equal to the legal driving limit (0.08%), with the exact dose adjusted according to
183 formulas accounting for participants' approximate body water (see Curtin & Fairchild, 2003).
184 Participants in the no-alcohol condition were administered a non-alcoholic beverage.

185 Following beverage administration, participants in the alcohol condition provided
186 breathalyzer readings at approximately 30-minute intervals until they left the lab. Participants in
187 the no-alcohol condition were breathalyzed upon arriving in the lab and then again immediately
188 post-drink. No-alcohol participants were allowed to leave after study tasks were completed (5-6
189 hours a sessions). Alcohol participants were required to remain until BrACs dropped below
190 0.025% and also SCRAM output registered at least one descending value (6-9 hour sessions).¹

191 *Apparatus*

192 The project involved multiple versions or “builds” of the Skyn device. These included
193 two builds representing early hand-assembled Skyn prototypes (referred to here as “Build 1” and
194 “Build 2”) shipped in 2018, and a third machine-made version shipped in 2019 (“Build 3”). Of

¹ Given the relatively substantial dose of alcohol administered in the current study, and the time required for alcohol metabolism, it was not feasible to keep participants in the lab to 0.00% BrAC. However, using the current procedures, we were able to capture the majority of the descending BAC limb for all participants.

195 the 256 participants assigned a Skyn device in this research, 66 were assigned a Build 1 device,
 196 51 a Build 2 device, and 131 a Build 3 device (device build information missing from 8
 197 participants).

198 *Data Analysis Plan*

199 Data analysis followed procedures employed in our previous research (Fairbairn et al.,
 200 2020). We estimated BrAC for a precise time point using TAC time series features (e.g., mean,
 201 trends, periodicity) extracted from Skyn during the immediately preceding 30-minute time
 202 interval. Time series features were extracted using the Python software package TSFRESH
 203 (Christ et al., 2018). To enable our model to learn across both alcohol and no-alcohol conditions
 204 we inserted 0.00% BrAC readings for control participants. Given that participants in both
 205 conditions were closely monitored during their laboratory visits and were not permitted to bring
 206 any personal belongings with them, it was conceivable to infer a 0.00% BrAC during sessions
 207 when no alcoholic beverage was administered. Thus, in order to simulate instances for the
 208 consumption of non-alcoholic beverages, we added synthetic 0.00% BrAC values every 10
 209 minutes. These additions ensured that predictions could also be produced for individuals who did
 210 not drink alcohol, and thus that model accuracy could also be examined for these scenarios.
 211 Further, across all experimental conditions, we added a single synthetic 0.00% baseline reading 1
 212 minute before drinking began in each session (see Fairbairn et al., 2020).

213 In total these procedures formed a set of 3,268 instances (input/output pairs). Importantly,
 214 to produce a model that might be applied for real-time BrAC estimation, we only included TAC
 215 time series *preceding* (not following) BrAC readings. Time series features were then entered into
 216 Extra-Trees machine learning algorithms (Geurts et al., 2006). We employed 4-fold, participant-
 217 independent cross-validation to ensure that predictions were not over-fit to specific data points or

218 participants. In this 4-fold procedure, we created a training set by randomly grouping participants
219 into four groups and a model was trained using data from three of those groups. During training,
220 we tuned hyperparameters for the Extra-Trees algorithm (e.g., tree size, diversity of trees) using
221 nested 4-fold cross-validation within training data only, to avoid overfitting hyperparameters to
222 test data. Once the training phase was complete, the model was subsequently tested on the fourth
223 group. This process was then repeated three more times to ensure that each participant was in the
224 testing set once.

225 Our primary evaluation metric is mean absolute error (*MAE*; i.e., *L1* distance)—the
226 average absolute difference between actual BrAC values and estimates of BrAC from
227 transdermal data (eBrAC). We report the mean of participant-level MAE values, calculating 95%
228 confidence intervals for the means via bootstrapping with 10,000 iterations (Efron, 1987). To
229 provide additional information, we also evaluate models through the following supplemental
230 metrics: 1) Root mean squared error (*RMSE*; i.e., *L2* distance); 2) Pearson's *r* between BrAC and
231 eBrAC across all observations, provided as a standardized effect size metric in line with effects
232 presented in prior transdermal publications (Davidson et al., 1997; Sakai et al., 2006); 3)
233 Standardized coefficients derived from mixed models, which assess the association between
234 eBrAC, entered as the predictor, and BrAC, entered as the outcome, while accounting for
235 participant-level clustering via random effects estimation (Raudenbush & Bryk, 2002).

236 Results

237 *Descriptives*

238 An average of 10 BrAC readings were collected from alcohol participants after beverage
239 administration. Average maximum BrAC was 0.083% (*SD*=0.016), and average (post-baseline)
240 minimum was 0.028% (*SD*=0.015). Of post-baseline alcohol condition BrAC values, 13% were

241 <0.03%, 22% were between 0.03%-0.05%, 30% were between 0.05%-0.07%, 28% were between
 242 .07-0.09%, and 7% were $\geq 0.09\%$. Refer to Table 1 for detailed descriptive statistics for Skyn
 243 TAC values.

244 *Device Failures*

245 In total, this research produced 61 missing Skyn files. Failure rates were attributable to a
 246 host of software and hardware-related issues. Specifically, 27 Skyn data files were either
 247 incomplete, severely truncated, entirely blank, or simply unusable due to device battery issues or
 248 failure to record data. There were also 15 instances in which our team experienced data transfer
 249 issues causing data loss, and an additional 19 lost files during the initial stages of this project as
 250 our team learned to work with the early delicate Skyn Builds (see Fairbairn, Kang, & Bosch,
 251 2020). Device failures were significantly more common in early hand-assembled Skyn
 252 prototypes (Builds 1 and 2) and became less common with later machine-made versions of Skyn
 253 (Build 3), $\chi^2(1, N = 256) = 37.70, p < 0.001$. Failure rates for Builds 1 and 2 were 29% and 53%
 254 respectively. In contrast, the failure rate for the later machine-made Build 3 was 7% (9 device
 255 failures yielded from 131 participants run). All participants for whom we had useable Skyn data
 256 were included in our final sample.

257 *Model Evaluation*

258 Across all participants and both alcohol and no-alcohol conditions, the average difference
 259 between actual BrAC and eBrAC (i.e., MAE) was 0.009, 95%CI [0.008, 0.010]. The average
 260 correlation between BrAC and eBrAC was $r=0.913$, 95%CI [0.907, 0.919] and RMSE was 0.012,
 261 95%CI [0.010, 0.013]. As in prior research (Fairbairn et al., 2020), here we found model
 262 accuracy to be lower (i.e., MAE higher) in the alcohol condition [$M=0.016, SD=0.013$] vs. the
 263 no-alcohol condition [$M=0.001, SD=0.004$], $b=0.015, SE=0.001, t=27.57, p<0.001$. Of note,

264 model accuracy did not differ significantly as a function of Skyn device build—a single model
 265 based on data from three distinct versions of the Skyn device yielded high accuracy irrespective
 266 of specific Skyn device build (see Table 2). *MAE* also did not differ significantly as a function of
 267 participant gender, age, or drinking patterns. Minor discrepancies emerged across racial
 268 categories, although relatively small sample sizes in specific racial categories indicate a need for
 269 replication of such effects (see Table 2 for full results). Follow-up model comparisons indicated
 270 that the combination of machine learning and time series methods outperformed more
 271 parsimonious models: a basic linear regression model produced an error that was more than
 272 double that of the final machine learning model, $MAE=0.021$, $95\%CI [0.019, 0.023]$, while a
 273 model employing machine learning methods but no time series analysis produced an error that
 274 was 56% higher than our final model, $MAE=0.014$ $95\%CI [0.012, 0.016]$. Graphs for “average”
 275 prediction cases produced by our final model appear in Figure 1.

276 Study 1 Discussion

277 This laboratory trial represents the largest study conducted to date validating transdermal sensors
 278 using objective alcohol measures (Fairbairn & Bosch, 2021). Results of this study indicate that
 279 error rates for more recent versions of new-generation transdermal sensors have improved
 280 markedly since earlier hand-made prototypes of these devices (Fairbairn et al., 2020; Fairbairn &
 281 Kang, 2019). It is important to note that while the device failure rates were somewhat higher for
 282 Build 2 compared to the earlier Build 1, the build dates were proximal and, further, our sample
 283 size for determining failure rates for Build 2 was substantially smaller ($k=2$ devices). Thus,
 284 failure rates for this slightly later version are less well approximated in the current research.

285 In addition, results provide further support for the notion that it is possible to create
 286 highly accurate real-time estimates of BrAC from transdermal data under controlled conditions,

287 and further that BrAC estimates based on machine learning outperform estimates based on
288 traditional regression-based approaches. However, and importantly, this study featured a single
289 fixed dose of alcohol and the laboratory context held constant many environmental factors (e.g.,
290 temperature, physical exertion, environmental alcohol) likely to impact the TAC-BAC link in
291 everyday contexts. As a result, although other performance indicators can be derived from such
292 laboratory studies, specific accuracy estimates based on this research carry little utility in
293 predicting transdermal sensor accuracy in real-world settings. Research exploring the
294 performance of these sensors in field contexts is key.

295

296 **Study 2**

297 **Methods**

298 *Participants*

299 Participants in the study consisted of young regular drinkers. Participants were recruited
300 from the psychology undergraduate subject pool at the University of Illinois. To ensure sufficient
301 frequency of drinking for ambulatory assessment, participants were required to consume alcohol
302 at least 3 times weekly in order to meet inclusion criteria for the study. A total of 26 individuals
303 underwent study procedures. The final sample consisted of the 23 individuals who complied with
304 experimental procedures and for whom we were able to obtain useable breathalyzer and Skyn
305 readings. The average age of participants in this study was 19 ($SD=1.5$). Regarding biological
306 sex, participants identified as 65% female and 35% male. Seventy four percent of participants
307 identified as White, 22% Asian, and 4% as multiracial.

308 *Procedures*

309 Participants in this study wore the Skyn transdermal sensor for 5 days while breathing

310 into a breathalyzer in response to prompted assessments on their smartphones as they went about
 311 their everyday lives. Devices employed in this study included only a single version of the Skyn
 312 device—the more recent machine-made version shipped in 2019 (“Build 3”). At study initiation,
 313 participants attended a laboratory visit during which they were trained to use the ambulatory
 314 survey platform (Metricwire Software; Trafford, 2016), the mobile breathalyzer, and the Skyn
 315 device. The BACtrack Mobile breathalyzer was chosen as a device with a compact/portable
 316 design that has proven to have strong correspondence with blood alcohol levels (Delgado et al.,
 317 2017). In order to reduce the chances that breathalyzer readings captured in everyday life would
 318 be biased by residual mouth alcohol, participants were instructed to wait before breathing into
 319 the breathalyzer if they had recently consumed an alcoholic beverage, and were also provided
 320 with a demonstration of the impact of mouth alcohol at their study initiation visit (i.e., Listerine
 321 mouth rinse followed by breathalyzer reading). Once Skyn was activated for a participant, the
 322 researchers trained them on how to use it. Specifically, participants were shown how to double
 323 check that the device was powered “on” and paired with their phone, as well as how to ensure
 324 that the Skyn data was syncing to the accompanying Skyn phone application. Of note, the
 325 ambulatory assessment period was scheduled to coincide with a weekend, to enhance the
 326 probability of capturing multiple drinking episodes during the 5-day study period.

327 During the ambulatory monitoring period, a schedule of assessments was employed
 328 intended to oversample moments of intoxication. More specifically, in line with procedures used
 329 in prior research (Piasecki et al., 2011, 2012), participants provided breathalyzer readings in
 330 response to three types of prompts: a) Random Prompts—these prompts sounded 6X/day during
 331 participants’ waking hours; b) User-Initiated Drinking Reports—participants were trained to log
 332 a user-initiated drinking report before taking the first sip of an alcoholic beverage in a drinking

333 episode; and c) Drinking Follow-Ups—once participants initiated a drinking report, they were
334 prompted to provide a breathalyzer reading every 30 minutes until three hours had passed.²
335 Further, in these surveys, participants had the option to indicate whether they believed a
336 breathalyzer reading they took was affected by mouth alcohol.
337 Data analysis followed the same procedures as in Study 1.

338 Results

339 *Descriptives*

340 Participants provided a total of 545 breathalyzer readings during engagement with the
341 study (an average of 24 readings/participant), with 245 of these readings provided while
342 participants were actively consuming alcohol. Over the course of the 5 days, participants
343 reported positive BAC readings on half of these days with an average of 2.3 days of drinking
344 across participants. For readings taken during drinking episodes, average BrAC was 0.094
345 ($SD=0.061$; *range* 0.007 to $>.2\%$). Descriptive statistics for the Skyn TAC values collected over
346 the course of the study are provided in Table 1.

347 *Data Loss and Device Failures*

348 Of our original sample of 26 participants, two were excluded from analyses because they
349 did not follow study procedures. Specifically, two participants failed to provide more than a
350 single verified breathalyzer reading and also failed to activate the Skyn device. Data from one
351 additional participant was lost for unknown reasons—it was unclear whether the issue was Skyn
352 device error or rather incorrect data transfer on the part of study personnel. The overall error rate

² In the final weeks of this research, we had to modify procedures in response to COVID-19. Thus, of the original sample of 26 participants, one participant engaged in a slightly modified version of study procedures. Modifications included: 1) All experimental visits were conducted online vs. in the laboratory; 2) Rather than completing user-initiated and follow-up assessments via Metricwire, an increased frequency of random assessments was employed (13X/day) and assessments were completed via the ambulatory survey platform Expiwell. All other study procedures were identical for this final participant vs the other 25 participants in the study.

353 for the machine-made Skyn devices (“Build 3”) employed in this study was 0%-4%. Of note, we
 354 also excluded BAC readings that were impacted by mouth alcohol. Two criteria were used to
 355 identify these readings including 1) any reading with a $BAC > .25$, and 2) any reading flagged as
 356 being affected by mouth alcohol by the participant.

357 *Model Evaluation*

358 Across all readings captured in this research, the average difference between actual BrAC
 359 and eBrAC (*MAE*) was 0.019, *95%CI* [0.015, 0.025]. The average correlation between BrAC and
 360 eBrAC was 0.816, *95%CI* [0.786, 0.842] and *RMSE* was 0.030, *95%CI* [0.023, 0.036]. Note that,
 361 even when sober instances ($BrAC=0.00\%$) were excluded outright from the model, BrAC and
 362 eBrAC were significantly correlated, $r=0.575$, *95%CI* [0.485, 0.655]. However, here as in our
 363 laboratory research, we found model accuracy to be significantly lower (i.e., *MAE* higher) when
 364 participants were consuming alcohol [$M=0.041$, $SD=0.031$] vs. when they were sober [$M=0.006$,
 365 $SD=0.012$], $b=0.033$, $SE=0.003$, $t=11.59$, $p<0.001$. *MAE* did not differ significantly as a function
 366 of participant gender, age, race, or drinking patterns (see Table 3 for full results). Follow-up
 367 model comparisons indicated that the combination of machine learning and time series methods
 368 outperformed more parsimonious models: a basic linear regression model produced an error that
 369 was approximately 80% higher than that of the final machine learning model, $MAE=0.034$,
 370 *95%CI* [0.028, 0.040].

371 **Integrative Analysis and Power Law Curve Projections**

372 In this section, we leveraged the combined strengths of Study 1 and Study 2 to offer a
 373 projection of the accuracy-level of transdermal alcohol sensors in future given adequately sized
 374 datasets for model training. Although Study 2 examined transdermal sensors in real-world
 375 conditions, the sample size of this study is extremely small for the purposes of machine learning

376 and thus results of Study 2 are unlikely to provide a clear picture of transdermal sensor
 377 performance in future given appropriately sized datasets. In contrast, although Study 1 examined
 378 transdermal sensors only in controlled laboratory contexts, the dataset has the advantage of being
 379 more optimally sized for data-driven model types (>3,000 BrAC readings used as outcomes in
 380 analysis), thus offering a clearer picture of potential increases in model accuracy given adequate
 381 data.

382 Here, leveraging data yielded by both studies, we provided a Power Law Curve
 383 projection—a function that offers predictions surrounding potential changes in model accuracy
 384 as the size of the training dataset increases (Cortes et al., 1994; Figueroa et al., 2012).
 385 Specifically, a power law curve was constructed by building machine learning models on the
 386 basis of data sub-divisions (e.g., 20%-90% of the final N) and estimating how model accuracy
 387 changes as the sample size increases. To construct a power law curve projection, we leveraged
 388 data from both laboratory and ambulatory samples, estimating the curve’s “starting value”
 389 through data yielded from the preliminary ambulatory sample ($MAE=0.019$, for all datapoints;
 390 $MAE=0.041$ for alcohol episodes), and estimating the power law curve “shape” through
 391 examining the extent to which accuracy increased with more data in the context of our larger
 392 laboratory study.

393 Based on projections that integrated all datapoints, including sober and intoxicated
 394 moments, we estimate MAE would reduce to <0.0137 given $N = 200$ (see Figure 2). In other
 395 words, if this projection were accurate, given access to larger ambulatory training datasets,
 396 transdermal estimates of BAC might ultimately be estimated to an accuracy level of 0.014% of
 397 true BAC. Given that, across both studies, the error of eBrAC values during drinking episodes
 398 exceeded error during non-drinking episodes, we repeated this projection excluding sober

399 moments ($eBrAC > 0.00$), yielding a projected *MAE* of 0.026% given $N = 200$. This value
 400 suggests that, given access to larger ambulatory training datasets, transdermal estimates of BAC
 401 during moments of intoxication might ultimately be estimated to an accuracy level of 0.026% of
 402 true BAC.

403 **Discussion**

404 The current study offers an updated account of the performance of new-generation
 405 transdermal sensors, providing what is to our knowledge among the first report of the accuracy
 406 of BAC estimates from new-generation transdermal devices in field contexts. Results of this
 407 study indicate that the most recent build of new-generation transdermal sensors demonstrates a
 408 substantially lower error rate compared to older hand-assembled prototypes of this sensor (0%-
 409 7% vs 29%-53%). Findings from our pilot ambulatory study indicate that, even given a small
 410 sample for model training ($N=23$) and large BrAC range (0.007% -> 0.2%), real-time estimates of
 411 BrAC yielded by transdermal sensors are on average within 0.019% of true BrAC readings taken
 412 in field contexts (0.041% for alcohol episodes). In addition, data from both laboratory and
 413 ambulatory studies indicate that machine learning models for translating TAC data yield
 414 significantly more accurate estimates of BAC compared to traditional analytic approaches, such
 415 as linear regression. Finally, results of power law curve analyses suggest that the accuracy of
 416 transdermal BAC estimates in field contexts have the potential to improve substantially given
 417 larger datasets for model training.

418 Results of this study indicate promise for this new generation of wrist-worn transdermal
 419 sensor. Note that prior iterations of wrist-worn transdermal sensors were plagued by high device
 420 failure rates (Marques & McKnight, 2009) and, when early hand-assembled prototypes of new-
 421 generation sensors were first examined, it appeared possible these new devices would be prone

422 to similar problems (Fairbairn & Kang, 2019). Thus, our report of low error rates for the latest
 423 build of new-generation sensors, including in field contexts, represents an auspicious result. In
 424 addition, results of this study provide the first BrAC estimates for new-generation transdermal
 425 sensors in a field context, indicating that, even in a severely underpowered pilot dataset,
 426 transdermal estimates of BrAC emerge as accurate to within 1-2 standard drinks (0.019-0.041%)
 427 of true BrAC. Importantly, all predictions yielded by this research represent “real-time” BrAC
 428 estimates—produced for a given time point based only on BrAC readings collected prior to that
 429 moment in time. Note that, in light of delays between the time alcohol is present in the blood and
 430 when it can be detected at the skin’s surface, many researchers have expressed doubt as to
 431 whether real-time estimation of intoxication from transdermal sensors would be feasible
 432 (Marques & McKnight, 2009). In this context, these preliminary findings are noteworthy.
 433 Finally, in the context of a transdermal sensor validation literature characterized by extremely
 434 small sample sizes (average $N < 20$; Fairbairn & Bosch, 2021), results of power law curve
 435 projections point to the importance of conducting transdermal sensor research featuring larger
 436 samples of participants. Specifically, projections suggest that underpowered studies are unlikely
 437 to yield accurate information on the capabilities for such sensors to predict alcohol use across
 438 individuals and contexts.

439 In addition, this work offers a glimpse at some of the challenges that lie ahead for the
 440 transdermal measurement of alcohol consumption. Results of this study indicate that the
 441 accuracy of transdermal estimates of BAC decreases as consumption level increases, with error
 442 emerging as larger during episodes of alcohol consumption vs. during sobriety. Thus, producing
 443 accurate transdermal estimates of BAC during intoxicated moments, including at higher BAC
 444 levels, represents a challenge for future research. Of note, although the 0.041% average error

445 yielded by this pilot field study is non-optimal for some applications, it is worth noting that even
446 this accuracy level may be sufficient for many transdermal alcohol sensor functions. More
447 specifically, beyond the precise quantification of BAC, a transdermal device capable of
448 categorizing drinking levels into broader, category-focused drinking measures (e.g., abstinence,
449 low risk, or high-risk drinking), and/or the identification of drinking episodes in near real time
450 might have a range of potential applications, including in prevention, intervention, and research.
451 In addition, power law curves indicate that the accuracy of machine learning estimates of BrAC
452 from transdermal data is likely to increase markedly given access to larger datasets for model
453 training. Future research should continue to explore the validity of new-generation sensor data
454 using objective drinking indicators in large samples under field conditions.

455 While it is unlikely that transdermal biosensors will replace traditional methods of BAC
456 measurement, they nonetheless represent a useful addition to our measurement toolkit. This new
457 tracking technology can potentially help researchers better understand the proximal and distal
458 factors driving alcohol use disorder risk and maintenance in naturalistic environments, thereby
459 enabling more targeted prevention efforts (Luczak et al., 2018; Piasecki, 2019). In therapeutic
460 contexts, the integration of such devices might provide fertile ground for conversation between
461 patients and their providers to create more individualized treatment plans as part of a harm
462 reduction approach (Barnett et al., 2015; Dougherty et al., 2014). Lastly, in the public health
463 domain the commercialization of such alcohol monitoring devices may allow consumers to gain
464 valuable insights into their drinking patterns and by extension minimize alcohol-related
465 morbidity and mortality (Fairbairn & Kang, 2020).

466 Additional limitations of this work should be noted. Prior research indicates that factors
467 varying within individuals across contexts can impact the TAC-BAC relationship. While we

468 were able to determine how our BAC estimations change as a function of demographic variables
 469 (e.g., gender and race), we were not able to isolate the influence of context-level variables such
 470 as sweating levels or rate of consumption (Piasecki, 2019; Saldich et al., 2021). Future research
 471 may choose to consider how such moderators affect the TAC-BAC relationship. Further, it is
 472 important to note that while we chose to analyze the data using a machine learning approach,
 473 other frameworks beyond linear regression exist that can be well suited for the modelling of
 474 complex relationships (Kryshchenko et al., 2021; Oszkinat et al., 2022; Sirlanci et al., 2018,
 475 2019). Specifically, first principles models require less data because they leverage expert
 476 knowledge to model for TAC-BAC translation; whereas machine learning approaches are more
 477 data-driven and can potentially uncover previously unknown associations between variables
 478 given enough data. Future work may aim to directly compare (and combine) these two modeling
 479 approaches. Finally, the need for additional field research incorporating larger samples has been
 480 indicated. It is worth noting, however, that the myriad factors that can interact to influence the
 481 TAC-BAC link may be difficult to parse using field methods alone. Well-powered laboratory
 482 studies with the potential to isolate metabolic and environmental influences on TAC (e.g.,
 483 drinking rate, sweating level, environmental alcohol) could be useful in isolating variable
 484 influences on the TAC-BAC relationship, thus training models to recognize distinct patterns
 485 associated with specific contextual factors and ultimately applying these to data collected in field
 486 contexts.

487 In summary, the current study offers updated information on the performance of the
 488 newest generation of transdermal alcohol biosensor. Findings indicate the latest version of these
 489 devices exhibit relatively low failure rates and hold promise for the assessment of alcohol
 490 consumption in field contexts. A great deal of additional work is left to be done before we have a

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

491 full picture of the utility of these devices. Nonetheless, with additional research, such passive
492 objective sensors hold potential for having a lasting impact on the manner in which researchers,
493 clinicians, and consumers might approach alcohol consumption assessment into the future.

494

495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516

References

Alessi, S. M., Barnett, N. P., & Petry, N. M. (2017). Experiences with SCRAMx alcohol monitoring technology in 100 alcohol treatment outpatients. *Drug and Alcohol Dependence, 178*, 417–424.

Ash, G. I., Gueorguieva, R., Barnett, N. P., Wang, W., Robledo, D. S., DeMartini, K. S., Pittman, B., Redeker, N. S., O’Malley, S. S., & Fucito, L. M. (2022). Sensitivity, specificity, and tolerability of the BACTrack Skyn compared to other alcohol monitoring approaches among young adults in a field-based setting. *Alcoholism: Clinical and Experimental Research, 46*(5), 783–796. <https://doi.org/10.1111/acer.14804>

Barnett, N. P. (2015). Alcohol sensors and their potential for improving clinical care. *Addiction, 110*(1), 1–3.

Barnett, N. P., Souza, T., Glynn, T. R., Luczak, S. E., Swift, R., & Rosen, I. G. (2015). The Transdermal Alcohol Sensor Macro (TASMAC): A rapid data processing tool for use with the SCRAMx alcohol sensor. *Alcoholism: Clinical & Experimental Research, 39*, 192A.

Caddy, G. R., Sobell, M. B., & Sobell, L. C. (1978). Alcohol breath tests: Criterion times for avoiding contamination by “mouth alcohol.” *Behavior Research Methods & Instrumentation, 10*(6), 814–818. <https://doi.org/10.3758/BF03205406>

Caluzzi, G., Pennay, A., Cook, M., Wright, C., Norman, T., & Kuntsche, E. (2019). Transdermal monitors to assess alcohol consumption in real-time and real-life—A qualitative study on user-experience. *Addiction Research and Theory, 27*(4), 354–361.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 517 Cherpitel, C. J., Ye, Y., Stockwell, T., Vallance, K., & Chow, C. (2018). Recall bias across 7
518 days in self-reported alcohol consumption prior to injury among emergency department
519 patients. *Drug and Alcohol Review*, 37(3), 382–388. <http://dx.doi.org/10.1111/dar.12558>
- 520 Christ, M., Braun, N., Neuffer, J., & Kempa-Liehr, A. W. (2018). Time series feature extraction
521 on basis of scalable hypothesis tests (tsfresh—a python package). *Neurocomputing*, 307,
522 72–77.
- 523 Cortes, C., Jackel, L. D., Solla, S. A., Vapnik, V., & Denker, J. S. (1994). Learning curves:
524 Asymptotic values and rate of convergence. *Advances in Neural Information Processing*
525 *Systems*, 327–334.
- 526 Curtin, J. J., & Fairchild, B. A. (2003). Alcohol and cognitive control: Implications for regulation
527 of behavior during response conflict. *Journal of Abnormal Psychology*, 112(3), 424–436.
528 <https://doi.org/10.1037/0021-843X.112.3.424>
- 529 Davidson, D., Camara, P., & Swift, R. (1997). Behavioral effects and pharmacokinetics of low-
530 dose intravenous alcohol in humans. *Alcoholism: Clinical and Experimental Research*,
531 21(7), 1294–1299.
- 532 Delgado, M. K., Huang, Y., Wanner, K., Goldberg, E., Hemmons, J., Spencer, E., & Wetherill,
533 R. (2017). Test accuracy of smartphone-paired breathalysers: A validation study. *Injury*
534 *Prevention*, 23.
- 535 Dougherty, D. M., Charles, N. E., Acheson, A., John, S., Furr, R. M., & Hill-Kapturczak, N.
536 (2012). Comparing the detection of transdermal and breath alcohol concentrations during
537 periods of alcohol consumption ranging from moderate drinking to binge drinking.
538 *Experimental and Clinical Psychopharmacology*, 20(5), 373–381.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 539 Dougherty, D. M., Hill-Kapturczak, N., Liang, Y., Karns, T. E., Cates, S. E., Lake, S. L., Mullen,
540 J., & Roache, J. D. (2014). Use of continuous transdermal alcohol monitoring during a
541 contingency management procedure to reduce excessive alcohol use. *Drug & Alcohol*
542 *Dependence, 142*, 301–306.
- 543 Efron, B. (1987). Better bootstrap confidence intervals. *Journal of the American Statistical*
544 *Association, 82*(397), 171–185.
- 545 Ernhart, C. B., Morrow-Tlucak, M., Sokol, R. J., & Martier, S. (1988). Underreporting of alcohol
546 use in pregnancy. *Alcoholism: Clinical and Experimental Research, 12*(4), 506–511.
- 547 Fairbairn, C. E., & Bosch, N. (2021). A new generation of transdermal alcohol biosensing
548 technology: Practical applications, machine learning analytics, and questions for future
549 research. *Addiction, 116*(10), 2912–2920.
- 550 Fairbairn, C. E., Bresin, K., Kang, D., Rosen, I. G., Ariss, T., Luczak, S. E., Barnett, N. P., &
551 Eckland, N. S. (2018). A multimodal investigation of contextual effects on alcohol's
552 emotional rewards. *Journal of Abnormal Psychology, 127*(4), 359–373.
553 <https://doi.org/10.1037/abn0000346>
- 554 Fairbairn, C. E., & Kang, D. (2019). Temporal dynamics of transdermal alcohol concentration
555 measured via new-generation wrist-worn biosensor. *Alcoholism: Clinical and*
556 *Experimental Research, 43*(10), 2060–2069. <https://doi.org/10.1111/acer.14172>
- 557 Fairbairn, C. E., & Kang, D. (2020). Transdermal alcohol monitors: Research, applications, and
558 future directions. In D. Frings & I. Albery (Eds.), *The Handbook of Alcohol Use and*
559 *Abuse*. Elsevier.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 560 Fairbairn, C. E., Kang, D., & Bosch, N. (2020). Using machine learning for real-time BAC
561 estimation from a new-generation transdermal biosensor in the laboratory. *Drug and*
562 *Alcohol Dependence*, 216, 108205. <https://doi.org/10.1016/j.drugalcdep.2020.108205>
- 563 Fairbairn, C. E., Rosen, I. G., Luczak, S. E., & Venerable, W. J. (2019). Estimating the quantity
564 and time course of alcohol consumption from transdermal alcohol sensor data: A
565 combined laboratory-ambulatory study. *Alcohol*, 81, 111–116.
566 <https://doi.org/10.1016/j.alcohol.2018.08.015>
- 567 Figueroa, R. L., Zeng-Treitler, Q., Kandula, S., & Ngo, L. H. (2012). Predicting sample size
568 required for classification performance. *BMC Medical Informatics and Decision Making*,
569 12(1), 8.
- 570 Frey, L. J., & Fisher, D. H. (1999, January 3). Modeling decision tree performance with the
571 power law. *Seventh International Workshop on Artificial Intelligence and Statistics*.
572 Seventh International Workshop on Artificial Intelligence and Statistics.
573 <https://proceedings.mlr.press/r2/frey99a.html>
- 574 Fridberg, D. J., Wang, Y., & Porges, E. (2022). Examining features of transdermal alcohol
575 biosensor readings: A promising approach with implications for research and
576 intervention. *Alcoholism: Clinical and Experimental Research*, 46(4), 514–516.
- 577 Geurts, P., Ernst, D., & Wehenkel, L. (2006). Extremely randomized trees. *Machine Learning*,
578 63(1), 3–42.
- 579 Gullberg, R. G. (1992). The elimination rate of mouth alcohol: Mathematical modeling and
580 implications in breath alcohol analysis. *Journal of Forensic Science*, 37(5), 1363–1372.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 581 Kryshchenko, A., Sirlanci, M., & Vader, B. (2021). Nonparametric Estimation of Blood Alcohol
582 Concentration from Transdermal Alcohol Measurements Using Alcohol Biosensor
583 Devices. In *Advances in Data Science* (pp. 329–360). Springer.
- 584 Leffingwell, T. R., Cooney, N. J., Murphy, J. G., Luczak, S., Rosen, G., Dougherty, D. M., &
585 Barnett, N. P. (2013). Continuous objective monitoring of alcohol use: Twenty-first
586 century measurement using transdermal sensors. *Alcoholism: Clinical and Experimental*
587 *Research*, 37(1), 16–22. <https://doi.org/10.1111/j.1530-0277.2012.01869.x>
- 588 Luczak, S. E., Hawkins, A. L., Dai, Z., Wichmann, R., Wang, C., & Rosen, I. G. (2018).
589 Obtaining continuous BrAC/BAC estimates in the field: A hybrid system integrating
590 transdermal alcohol biosensor, Intellidrink smartphone app, and BrAC Estimator
591 software tools. *Addictive Behaviors*, 83, 48–55.
- 592 Luczak, S. E., & Ramchandani, V. A. (2019). Special issue on alcohol biosensors: Development,
593 use, and state of the field. *Alcohol*, 81, 161–165.
- 594 Luczak, S. E., & Rosen, I. G. (2014). Estimating BrAC from transdermal alcohol concentration
595 data using the BrAC estimator software program. *Alcoholism: Clinical and Experimental*
596 *Research*, 38(8), 2243–2252. <https://doi.org/10.1111/acer.12478>
- 597 Marques, P. R., & McKnight, A. S. (2009). Field and laboratory alcohol detection with 2 types of
598 transdermal devices. *Alcoholism: Clinical and Experimental Research*, 33(4), 703–711.
- 599 Merrill, J., Gunn, R., Neary, A., Souza, T., & Barnett, N. (2022). Feasibility and Acceptability of
600 a Wrist-worn Transdermal Alcohol Biosensor to Collect Data in the Field. *Proceedings of*
601 *the 55th Hawaii International Conference on System Sciences*.
- 602 Mjolsness, E., & DeCoste, D. (2001). Machine learning for science: State of the art and future
603 prospects. *Science*, 293(5537), 2051–2055.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 604 National Advisory Council on Alcohol Abuse and Alcoholism. (1989). *Recommended Council*
605 *Guidelines on Ethyl Alcohol Administration on Human Experimentation*.
- 606 Nyman, E., & Palmlov, A. (1936). The Elimination of Ethyl Alcohol in Sweat. *Skandinavisches*
607 *Archiv Für Physiologie*, 74(2), 155–159. [https://doi.org/10.1111/j.1748-](https://doi.org/10.1111/j.1748-1716.1936.tb01150.x)
608 1716.1936.tb01150.x
- 609 Oszkinat, C., Luczak, S. E., & Rosen, I. G. (2022). Uncertainty Quantification in Estimating
610 Blood Alcohol Concentration From Transdermal Alcohol Level With Physics-Informed
611 Neural Networks. *IEEE Transactions on Neural Networks and Learning Systems*, 1–8.
612 <https://doi.org/10.1109/TNNLS.2022.3140726>
- 613 Piasecki, T. M. (2019). Assessment of alcohol use in the natural environment. *Alcoholism:*
614 *Clinical and Experimental Research*, 43(4), 564–577.
615 <http://dx.doi.org/10.1111/acer.13975>
- 616 Piasecki, T. M., Jahng, S., Wood, P. K., Robertson, B. M., Epler, A. J., Cronk, N. J., Rohrbaugh,
617 J. W., Heath, A. C., Shiffman, S., & Sher, K. J. (2011). The subjective effects of alcohol–
618 tobacco co-use: An ecological momentary assessment investigation. *Journal of Abnormal*
619 *Psychology*, 120(3), 557–571. <https://doi.org/10.1037/a0023033>
- 620 Piasecki, T. M., Wood, P. K., Shiffman, S., Sher, K. J., & Heath, A. C. (2012). Responses to
621 alcohol and cigarette use during ecologically assessed drinking episodes.
622 *Psychopharmacology*, 223(3), 331–344. <https://doi.org/10.1007/s00213-012-2721-1>
- 623 Raudenbush, S. W., & Bryk, A. S. (2002). *Hierarchical linear models: Applications and data*
624 *analysis methods* (Vol. 2). Sage Publications.
- 625 Russell, M. A., Turrisi, R. J., & Smyth, J. M. (2022). Transdermal sensor features correlate with
626 ecological momentary assessment drinking reports and predict alcohol-related

- 627 consequences in young adults' natural settings. *Alcoholism: Clinical and Experimental*
628 *Research*, 46(1), 100–113.
- 629 Sakai, J. T., Mikulich-Gilbertson, S. K., Long, R. J., & Crowley, T. J. (2006). Validity of
630 transdermal alcohol monitoring: Fixed and self-regulated dosing. *Alcoholism: Clinical*
631 *and Experimental Research*, 30(1), 26–33.
- 632 Saldich, E. B., Wang, C., Rosen, I. G., Bartroff, J., & Luczak, S. E. (2021). Effects of stomach
633 content on the breath alcohol concentration-transdermal alcohol concentration
634 relationship. *Drug and Alcohol Review*, 40(7), 1131–1142.
- 635 Sirlanci, M., Luczak, S. E., Fairbairn, C. E., Kang, D., Pan, R., Yu, X., & Rosen, I. G. (2019).
636 Estimating the distribution of random parameters in a diffusion equation forward model
637 for a transdermal alcohol biosensor. *Automatica*, 106, 101–109.
638 <https://doi.org/10.1016/j.automatica.2019.04.026>
- 639 Sirlanci, M., Rosen, I. G., Luczak, S. E., Fairbairn, C. E., Bresin, K., & Kang, D. (2018).
640 Deconvolving the input to random abstract parabolic systems: A population model-based
641 approach to estimating blood/breath alcohol concentration from transdermal alcohol
642 biosensor data. *Inverse Problems*, 34(12), 125006.
- 643 Swift, R. M. (2003). Direct measurement of alcohol and its metabolites. *Addiction*, 98(s2), 73–
644 80.
- 645 Swift, R. M., & Swette, L. (1992). Assessment of ethanol consumption with a wearable,
646 electronic ethanol sensor/recorder. In R. Z. Litten & J. P. Allen (Eds.), *Measuring alcohol*
647 *consumption: Psychosocial and biochemical methods*. (pp. 189–202). Humana Press.
- 648 Trafford, E. (2016). *MetricWire (Version 2.2.10)[Mobile application software]*.

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY

- 649 Wang, Y., Fridberg, D. J., Leeman, R. F., Cook, R. L., & Porges, E. C. (2019). Wrist-worn
650 alcohol biosensors: Strengths, limitations, and future directions. *Alcohol: A Biomedical*
651 *Journal*, *81*, 83–92.
- 652 Wang, Y., Fridberg, D. J., Shortell, D. D., Leeman, R. F., Barnett, N. P., Cook, R. L., & Porges,
653 E. C. (2021). Wrist-worn alcohol biosensors: Applications and usability in behavioral
654 research. *Alcohol: A Biomedical Journal*, *92*, 25-34. White, A. M. (2003). What
655 happened? Alcohol, memory blackouts, and the brain. *Alcohol Research and Health*,
656 *27*(2), 186–196.
- 657
658

TRANSDERMAL ALCOHOL BIOSENSORS: A LAB AND FIELD STUDY


659 **Figure Legends**

660 **Figure 1**

661 *Graphs for participants with average (Median MAE) prediction accuracy from both alcohol and*
662 *no-alcohol conditions in Study 1*

663

664



666

667 *Note.* For the purposes of graphs displayed here, data from Skyn was transformed (divided by
668 20,000) such that it could be visualized on approximately the same scale as eBrAC and BrAC.

669

670

671 **Figure 2**

672 *Power law curve projections of potential increases in the accuracy of transdermal BAC*
673 *estimates in real-world contexts as sample size available for model training increase. Of note the*
674 *figure above denotes estimates for overall level BrAC (and not participant-level eBAC).*

675

676

677




Table 1

Skyn TAC values descriptive statistics

	Study 1	Study 2
Skyn 5th percentile:	342.0	417.0
Skyn 50th percentile:	465.0	436.67
Skyn 95th percentile:	1970.28	1051.02

Note. The Skyn units represent a measure of raw current defined at the sensor.

679

680

Table 2

MAE as a function of participant and device characteristics in Study 1

	<i>b</i>	<i>SE</i>	<i>t</i>	<i>p</i>
Gender	-0.0009	0.0005	-1.60	0.1113
Age	0.0002	0.0002	0.81	0.4211
Days Drink/30	-0.0001	0.0001	-1.74	0.0833
Race				
White	0.0009	0.0008	1.20	0.2331
Black	0.0013	0.0011	1.23	0.2184
Asian	0.0020	0.0010	1.98	0.0492
Skyn Version				
Build 1	-0.0006	0.0007	-0.80	0.4227
Build 2	0.0003	0.0010	0.30	0.7626

Note. The above represent coefficients derived from multilevel models predicting *MAE* (average absolute distance between measured BrAC and eBrAC) while accounting for clustering of observations within participants. All variables were entered into separate models. All models control for beverage condition assignment.

Gender was coded such that Female=1 and Male=0. “Days Drink/30”=number of days reported drinking at baseline out of past 30; Race was coded as a set of dummy codes, with “Other/Multiracial” as the reference group; Skyn Version was coded as a set of dummy codes, with Build 3 as the reference group.

681
682
683

Table 3

MAE as a function of participant and device characteristics in Study 2

	<i>b</i>	<i>SE</i>	<i>t</i>	<i>p</i>
Gender	-0.004	0.006	-0.71	0.483
Age	0.001	0.002	0.43	0.672
Days Drink/30	0.0002	0.0004	0.46	0.649
Race				
White	0.007	0.003	2.03	0.056
Asian	-0.004	0.003	-1.51	0.145

Note. The above represent coefficients derived from multilevel models predicting *MAE* (average absolute distance between measured BrAC and eBrAC) while accounting for clustering of observations within participants. All variables were entered into separate models.

Gender was coded such that Female=1 and Male=0. “Days Drink/30”=number of days reported drinking at baseline out of past 30; Race was coded as a set of dummy codes, with “Other/Multiracial” as the reference group.

684

685

686